Oxygenta Pharmaceutical Share Price
Small Cap | Pharmaceuticals and health care | BSE: 524636
₹77.43 
-1.58 (-2.00 %)
Last Updated: 13 Mar 2025 12:00 AM
BEARISH
Overview
Open (₹) 78.62
High (₹) 78.62
Low (₹) 77.43
Prev. Close (₹) 79.01
Volume 3,701
VWAP (₹) 74.97
ROCE (%) -41.74
Industry P/E 43.95
TTM P/E -1935.75
P/B Ratio -12.88
Market Cap (₹) Cr.286.36
Dividend Yield (%)--
EPS (₹) -1.04
ROE17.30%
Sales Growth (%) 27.93
Profit Growth (%)-69.93
Day Range
78.6278.62
52 Week Range
27.62108.64
Historical Returns
Returns (6M)
37.65 %
Returns (1Y)
167.83 %
Returns (3Y)
244.13 %
Returns (5Y)
709.09 %
Returns (6M)
37.65 %
Returns (1Y)
167.83 %
Returns (3Y)
244.13 %
Returns (5Y)
709.09 %
SWOT Analysis
- Growth in Net Profit Margin (QoQ)
- Increasing Revenue every Quarter for the past 4 Quarters
- Strong long-term momentum: Price above long-term moving averages (EMA_200)
- Price above the pivot point indicates bullish sentiment.
Technicals
Technical Rating
BEARISHRSI 47.62
MFI 17.15
ATR 2.74
Commodity Channel Index -123.59
ROC125 96.13
ROC21 -1.37
Williams %R -100.00
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 74.98 | 75.03 | 75.06 | 74.95 | 74.90 | 74.87 | 74.82 |
| Week Ago | 81.01 | 81.18 | 81.26 | 80.93 | 80.76 | 80.68 | 80.51 |
| Month Ago | 78.97 | 81.58 | 84.51 | 76.04 | 73.43 | 70.50 | 67.89 |
EMA & SMA
77.43
Current Price
Bullish Moving Averages
2
Bearish Moving Averages
18
5 Day 78.88
9 Day 80.82
10 Day 81.54
12 Day 83.86
14 Day 84.50
20 Day 82.82
26 Day 81.81
50 Day 83.46
100 Day 85.73
200 Day 62.01
Deals & Announcements
Bulk and Block Deals
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 13 Dec, 2024 | Raghavender Rao Kanuganti Revised | Disposal | ₹15.00 | 8,00,000 | BSE |
| 13 Dec, 2024 | M V S Prasad Reddy Revised | Acquisition | ₹15.00 | 8,00,000 | BSE |
| 13 Dec, 2024 | M V S Prasad Reddy Revised | Acquisition | ₹15.00 | 69,52,600 | BSE |
| 04 Oct, 2024 | Raghavender Rao Kanuganti | Disposal | ₹0.00 | 8,00,000 | BSE |
| 03 Oct, 2024 | M V S Prasad Reddy | Acquisition | ₹0.00 | 8,00,000 | BSE |
| 30 Sept, 2024 | M V S Prasad Reddy | Acquisition | ₹0.00 | 69,52,600 | BSE |
| 04 Sept, 2021 | Sai Sudhakar Vankineni | Disposal | ₹10.00 | 5,00,000 | BSE |
| 04 Sept, 2021 | Snigdha Vankineni | Acquisition | ₹10.00 | 5,00,000 | BSE |
Corporate Actions
No corporate actions available.
Announcements
| Date | Source | Detail |
|---|---|---|
| 08 Mar, 2025 | BSE India | Mark Corporate Advisors Pvt Ltd. (\Manager to the Offer\) has submitted to BSE a copy of Post Offer Advertisement under Regulation 18(12) of SEBI (SAST) Regulations, 2011, and amendments thereto (\SEBI (SAST) Regulations, 2011\) for the attention of the Public Shareholders of Oxygenta Pharmaceutical Ltd (\Target Company\). |
| 14 Feb, 2025 | BSE India | Unaudited financial results for the Quarter ended December 31,2024. |
| 14 Feb, 2025 | BSE India | Un Audited Financial results for the Quarter ended December 31,2024. |
| 08 Feb, 2025 | BSE India | Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the company will be held on Friday, February 14, 2025, inter alia, to consider the Un-audited financial results of the Company for the Third quarter ended on December 31, 2024 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.\r\nIn continuation to our earlier intimation of closure of trading window, we would like to inform that the trading window of the Company for all the designated persons and their immediate relatives will remain closed till February 16, 2025, which is 48 hours after the said Board Meeting. \r\nThis is for your information and records. |
| 06 Feb, 2025 | BSE India | Mark Corporate Advisors Pvt Ltd. (\Manager to the Offer\) has submitted to BSE a copy of Offer Opening Public Announcement under Regulation 18(7) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended, for the attention of the eligible equity shareholders of Oxygenta Pharmaceutical Ltd (\the Company\). |
| 04 Feb, 2025 | BSE India | Independent Directors Committee (IDC) have submitted to BSE recommendations under Regulation 26(7) of SEBI (SAST) Regulations, 2011, for the Open Offer to Public Shareholders of Oxygenta Pharmaceutical Ltd. |
| 31 Jan, 2025 | BSE India | Mark Corporate Advisors Pvt Ltd. (\Manager to the Offer\) has submitted to BSE a copy of Letter of Offer for the attention of the eligible equity shareholders of Oxygenta Pharmaceutical Ltd (\the Company\). |
| 17 Jan, 2025 | BSE India | The Certificate issued by the RTA dated 03.01.2025 attached herewith |
| 14 Nov, 2024 | BSE India | Board of Directors approved the Un Audited Results for the Half year and Second quarter ended on September 30, 2024. |
| 07 Nov, 2024 | BSE India | Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the company will be held on Thursday, November 14, 2024, inter alia, to consider the Un-audited financial results of the Company for the Second quarter ended on September 30, 2024 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.\r\nIn continuation to our earlier intimation of closure of trading window, we would like to inform that the trading window of the Company for all the designated persons and their immediate relatives will remain closed till November 16, 2024, which is 48 hours after the said Board Meeting. \r\nThis is for your information and records. |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 11 Feb, 2025 | 14 Feb, 2025 |
| Quarterly Results | -- | 08 Nov, 2024 | 14 Nov, 2024 |
| Quarterly Results | -- | 09 Aug, 2024 | 14 Aug, 2024 |
| Audited Results | -- | 24 May, 2024 | 30 May, 2024 |
| Others | Inter-alia, to consider : 1. Raising of funds by way of issue of Equity Shares on preferential basis. | 04 Apr, 2024 | 08 Apr, 2024 |
| Quarterly Results | -- | 07 Feb, 2024 | 14 Feb, 2024 |
| Quarterly Results | -- | 07 Nov, 2023 | 14 Nov, 2023 |
| Quarterly Results | -- | 09 Aug, 2023 | 14 Aug, 2023 |
| Audited Results | -- | 25 May, 2023 | 30 May, 2023 |
| Preferential issue of shares | -- | 24 Feb, 2023 | 27 Feb, 2023 |
Share Holding Pattern
| Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
|---|
About Oxygenta Pharmaceutical
Oxygenta Pharmaceutical is a Public Limited Listed company incorporated on 27/11/1990 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24110TG1990PLC012038 and registration number is 012038. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 39.64 Cr. and Equity Capital is Rs. 33.48 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1990
Managing Director
Dr. Sai Sudhakar Vankineni
NSE Symbol
--
Oxygenta Pharmaceutical Management
| Name | Designation |
|---|---|
| Dr. Sai Sudhakar Vankineni | Chairperson & Managing Director |
| Mr. Raghavender Rao Kanuganti | Executive Director |
| Mr. Sunil Vishram Chawda | Executive Director |
| Mrs. Sravani Reddy Gantla | Executive Director |
| Mr. Bharath Reddy Guntuku | Ind. Non-Executive Director |
| Mr. Vidya Sagar Devabhaktuni | Ind. Non-Executive Director |
| Mr. Sanagari Kondal Reddy | Ind. Non-Executive Director |
| Mrs. Padmaja Surapureddy | Ind. Non-Executive Director |
| Mrs. Aakanksha Sachin Dubey | Addnl.Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| Sun Pharmaceutical Industries | ₹4,03,916.05 | ₹1,683.45  ₹1,676.85(0.39%) | ₹1,376.750 - ₹1,960.200 |
| Divi's Laboratories | ₹1,49,205.29 | ₹5,620.45  ₹5,667.15(-0.82%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,18,065.23 | ₹1,461.90 ₹1,454.30(0.52%) | ₹1,317.600 - ₹1,702.000 |
| Torrent Pharmaceuticals | ₹1,03,430.62 | ₹3,056.05 ₹3,096.50(-1.31%) | ₹2,488.000 - ₹3,589.950 |
| Dr. Reddy's Laboratories | ₹92,453.48 | ₹1,107.95 ₹1,105.15(0.25%) | ₹1,093.000 - ₹1,420.200 |
FAQs on Oxygenta Pharmaceutical
What is the share price of Oxygenta Pharmaceutical?
The share price of Oxygenta Pharmaceutical on 13 Mar, 2025 is ₹ 77.43.
What is 52W high and 52W low share price of Oxygenta Pharmaceutical?
The highest and lowest 52W share prices of Oxygenta Pharmaceutical are ₹ 108.640 and ₹ 27.620
What is the market cap of Oxygenta Pharmaceutical?
The market capitalization of Oxygenta Pharmaceutical as of 13 Mar, 2025 is ₹ 286.36 Crores
What is the P/E ratio of Oxygenta Pharmaceutical?
The current P/E ratio of Oxygenta Pharmaceutical as of 13 Mar, 2025 is 43.95
What is the PB ratio of Oxygenta Pharmaceutical?
The PB ratio of Oxygenta Pharmaceutical as of 13 Mar, 2025 is -12.88
Top Gainers
₹41.02
₹34.29 (0.20%)
₹8.84
₹7.37 (0.20%)
₹6.97
₹5.81 (0.20%)
₹194.70
₹162.25 (0.20%)
Top Losers
₹13.75
₹135.15 (-0.90%)
₹9.60
₹12.00 (-0.20%)
₹9.80
₹93.55 (-0.90%)
₹0.99
₹4.77 (-0.79%)
Market Indices
Sensex
₹73,828.91
₹74,029.76 (0.00%)